IL17A and asthma: A single clinical trial evaluating the effectiveness of secukinumab, an anti-IL-17A human IgG1κ monoclonal antibody, in poorly controlled asthma was terminated prior to completion with the caveat that future clinical trials involving this biologic require an extensive overhaul, including modifications to the study design, endpoints, and population as well as the use of a different anti-IL-17A antibody [101, 102].